Thursday, 24 April 2014

Antibody Drug Conjugates (ADCs) a new type of compound that potentially cures end-stage terminal patients

How does a new class of cancer drug, called Antibody Drug Conjugate, eliminate 70 lethal tumors within a terminal patient in just two weeks.  


Antibody Drug Conjugate (ADC) treatment for cancer results in complete remission - cure - Brentuximab vedotin
Before (left) and after (right) treatment scans. The image on the left 
shows the extent of metastatic disease (spread of cancer) in the 
patient (70 tumours from Non-Hodgkin's Lymphoma). The scan on 
the right demonstrates complete elimination of tumours two weeks 
after treatment (the black blobs in the scan on the right are normal 
(these are the brain, kidneys, and the bladder).
Various media outlets recently reported that a 47 year old man in the UK with only weeks to live, made a full recovery from his terminal Non-Hodgkin’s Lymphoma cancer following treatment with a recently approved drug called Brentuximab vedotin (Adcetris). His body, as seen in the scan on the left, was riddled with approximately 70 fatal tumours. These tumours had spread to distant sites throughout his body, yet within a space of two weeks all these tumours had disappeared. The drug responsible for this remarkable recovery is part of a new class of immunotherapeutics called Antibody Drug Conjugates (ADCs). Although the therapy itself wasn’t a particularly pleasant experience (apparently the patient didn’t feel well for the first few days), it gave the patient a choice; death within a couple of weeks or a chance to be in complete remission. ADCs are also being developed for cancer of the lung, colon, prostate, brain and other solid tumours as well as leukaemia. Approximately 40 ADCs are currently undergoing clinical trials (see the enclosed list below with details and links to clinical trials).

In this article I will discuss the following:

  1. What is Brentuximab vedotin (Adcetris)?
  2. What are Antibody Drug Conjugates (ADC)?
  3. Different technologies and compounds that make up an ADC
  4. The biotech and pharmaceutical companies that are developing ADCs for other cancers
  5. List and links to current clinical trials investigating ADCs for other cancers

For info about Biozantium by Paeon Laboratories:  http://www.biozantium.com
Pages: 1 2 3 4 5

No comments:

Post a Comment